Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate that is highly effective in patients with relapsed/refractory anaplastic large cell lymphoma (ALCL).
patients with relapsed/refractory ALCL who have received BV with a secondary focus on survival after progression following BV. A total of 56 patients were treated with BV for relapsed or refractory ALCL. The overall response rate to BV was 73% with complete response (CR) rate of 46%. The median failure-free survival and overall survival (OS) after BV were 15.5 month and not reached, respectively. The median duration of response was 27.6 months in patients who achieved CR by BV, while the median OS of those who did not achieve CR by BV was 9.5 months. There was no significant difference in OS between those who underwent stem cell transplant (SCT) and those who did not in patients who achieved CR after BV. However, if patients were in PR after BV, SCT was associated with significantly longer OS. Thirty patients experienced progressive disease on BV or required a subsequent treatment.
The median OS after BV failure was 2.9 months with 2-year OS of 27.1%. There were seven long-term survivors (≥12 months) following failure. After an adequate response to subsequent salvage therapy, five patients underwent subsequent SCT (three allogeneic and two autologous), four of which were long-term survivors (17+, 25+, 32+, and 50+ months). In conclusion, BV failure is associated with a poor outcome in patients with ALCL, which defines a small but important group with unmet need. SCT may have benefit in patients with relapsed/refractory ALCL who failed BV.
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| INTRODUCTION
Systemic anaplastic large cell lymphoma (ALCL) is a distinct subtype of peripheral T-cell lymphoma. 1 The hallmark of the disease is strong CD30 positivity, and the disease is further subcategorized by the status of ALK expression. 2 The commonly used frontline therapy is CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) 1 which is associated with 5-year progression-free survival rate in patients with ALK positive ALCL and ALK negative ALCL of approximately 60% to 80% and 30% to 50%, respectively. 3 For refractory or recurrent ALCL, safe and effective therapy is needed. 4, 5 Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate that has a significant activity in ALCL and classical Hodgkin lymphoma. In a pivotal phase II study of BV in patients with relapsed/ refractory systemic ALCL, the ORR and complete response (CR) rate were 86% and 57%, respectively. 6 The median progression-free survival and median duration of response were 13.3 months and 12.6 months, respectively. 6 The study also showed its excellent tolerability with the most common toxicity observed being peripheral neuropathy. With study follow-up of 5 years, the 5-year overall survival (OS) was 60%, the median duration of response for patients who achieved CR was still not reached, and 14% of the trial population still remained CR in the absence of transplant. 7 Based on remarkable efficacy as well as generally good tolerability, BV is considered a standard treatment for patients with relapsed/refractory ALCL.
Retreatment with BV is often effective in patients who once had a benefit from BV. 8 In one study, objective response was observed in seven of eight patients (88%) with CR in five patients (63%). Median response duration was 12.3 months (range: 6.6 to 28.0+ months).
However, once disease either progression on treatment or relapse following a remission occurs, treatment options are limited. Further, the outcome of patients following BV failure remains unknown. Herein, we retrospectively analyzed patients with systemic ALCL who received BV for relapsed/refractory disease and report the outcome following BV failure.
| PATIENTS AND METHODS
All patients treated with BV for relapsed/refractory ALCL were The median duration of response was 27.6 months (95%CI:
15.6 months-not reached) in patients who achieved CR by BV, while the median OS of those who did not achieve CR by BV was 9.5 months (95%CI: 4.8-19.8 months). There were no significant differences in CR rate, FFS, and OS in patients between who received or did not receive SCT prior to BV (data not shown).
Twenty-two patients underwent SCT (auto n = 13; allo n = 9)
following response to BV. There was no significant difference in OS between those who underwent SCT and those who did not in patients who achieved CR after BV ( Figure 1B) . However, if patients were in PR after BV, SCT was associated with significantly longer OS (Supplemental Figure 1A) . The median FFS in patients who underwent SCT in PR was not reached while the median FFS in those who achieved PR but did not underwent SCT was 13.8 months. There was no difference in OS after SCT between patients who received auto-SCT or allo-SCT (Supplemental Figure 1B) . In total, seven patients (13%) received BV alone without SCT and remain in complete remission. There was no death due to BV toxicities. 
| DISCUSSION
We confirm that the response and survival after BV in patients with relapsed/refractory ALCL were favorable, similar to the results of pivotal phase II trial. 6, 7 Sustained remission even after discontinuation of BV was also seen in 12/22 patients (54%) who did not proceed to SCT in the phase II trial showing that proportion of relapsed/refractory ALCL can be cured by BV alone. 7 In the current study, seven of 26 (27%) who achieved CR after BV remain in remission without SCT.
On the other hand, the outcome of patients who experience disease progression after BV remains very poor. If CR was not achieved after BV and SCT were not performed, the median OS after starting BV was only 4.3 months (95%CI: 2.1-8.3 months) (Supplemental Figure 1C) . Further, median OS following BV failure was 2.9 months.
Most of the long-term survivors in this population were those who eventually had adequate response to the next therapy and went onto SCT. The 5-year OS after auto-SCT for relapsed/refractory disease with ALCL was 57% in both ALK+ALCK and ALK-ALCL from a MDACC study, suggesting that ALCL patients who have chemosensitive disease can have benefit from auto-SCT. 4 Although allo-SCT may provide long-term remission, 10 allo-SCT is associated with relatively high mortality which can potentially harm the OS, 11 and thus indication should be carefully discussed with each patient.
In conclusion, BV failure is associated with a poor outcome in patients with ALCL, which defines a small but important group with unmet need.
